Friday, October 1, 2021
The trial’s direct implications are huge. Serious questions have been raised about the logic of pursuing pharmacies for opioids. Take, for example, the Wall Street Journal Editorial Board, which critiqued pharmacy lawsuits while noting that “Walmart and CVS didn’t push opioids on their customers[,] [n]or did they break the law when they distributed opioids to their pharmacies, which fill valid prescriptions written by state-licensed doctors and often approved by the state-run Medicaid or federal Medicare programs.” This trial will help define winners and losers in that high-profile debate, with billions at stake.
Some plaintiffs lawyers are already checking out the Gulfstream website, I bet.